Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multiple-dose, Adaptive Design Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

NCT06094725 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT06094725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06094725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multiple-dose, Adaptive Design Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
Lead sponsor
Corcept Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
January 6, 2020
Completion date
December 14, 2020
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment